Image Source: Tachs, CC BY-SA 4.0, via Wikimedia Commons
Aster DM Healthcare Limited (ASTERDM) has achieved a major milestone in its ongoing corporate restructuring process.
The company announced that it has received “No Objection” letters with no adverse observations from both BSE Limited and the National Stock Exchange of India Limited (NSE) for its proposed scheme of amalgamation.
This regulatory clearance pertains to the proposed merger of Quality Care India Limited (the Transferor Company) with and into Aster DM Healthcare Limited (the Transferee Company).
The scheme of merger operates under Sections 230-232 of the Companies Act, 2013.
The boards of directors for both companies had previously approved the Scheme on November 29, 2024, contingent upon securing applicable regulatory and other approvals.
The receipt of the No Objection letters, dated October 06, 2025, signifies that the stock exchanges have reviewed the draft scheme concerning its bearing on listing/de-listing/continuous listing requirements.
However, investors should note that the submission of documents to the exchanges should not be construed as the scheme being cleared or approved by SEBI or the exchanges.
The exchanges specifically state they do not take any responsibility for the financial soundness of the scheme or the correctness of the statements made in the submitted documents.
While the observation letters conveyed ‘no adverse observations,’ the regulatory bodies, based on SEBI’s comments, provided numerous detailed instructions that Aster DM Healthcare must adhere to before implementation.
...Disclaimer: The information provided is for educational purposes only and does not constitute financial advice. We are not registered financial advisors. Please conduct your own research and consult a qualified advisor before making investment decisions. Any investment decisions you make based on this information are solely at your own risk.
